Literature DB >> 11531277

DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization.

A Ahluwalia1, P Yan, J A Hurteau, R M Bigsby, S H Jung, T H Huang, K P Nephew.   

Abstract

OBJECTIVE: The aim of this study was to examine CpG island methylation patterns in ovarian cancer and determine whether epigenetic information can be related to clinical data of patients. CpG island (CpGI) hypermethylation is commonly associated with cancer progression, but little is currently known about the role of methylation in ovarian cancer.
METHODS: Differential methylation hybridization (DMH) analysis at 742 loci was performed to determine methylation signatures for 20 primary epithelial ovarian carcinomas (Stages II, III, and IV adenocarcinomas, serous papillary), 6 ovarian cancer cell lines, and normal ovarian surface epithelial cells.
RESULTS: Between 23 and 108 methylated CpGIs were seen in the ovarian carcinomas. Fewer (P < 0.05) methylated CpGIs were observed in the ovarian cancer cell lines; however, a number of CpGIs were commonly hypermethylated in both the cell lines and the tumor samples. A methylation signature, consisting of frequently (P < 0.05) methylated CpGIs, was determined for the samples. The observed pattern of methylation in ovarian cancers included several (11) CpGI tags that were previously reported to be hypermethylated in human breast cancer.
CONCLUSIONS: Epigenetic signatures in ovarian cancer were determined using DMH. This proof-of-concept study lays the foundation for genome-wide screening of methylation to examine epigenotype-phenotype relationships in ovarian cancer. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531277     DOI: 10.1006/gyno.2001.6291

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  26 in total

Review 1.  Techniques used in studies of epigenome dysregulation due to aberrant DNA methylation: an emphasis on fetal-based adult diseases.

Authors:  Shuk-mei Ho; Wan-yee Tang
Journal:  Reprod Toxicol       Date:  2007-01-19       Impact factor: 3.143

2.  Epigenetic determinants of ovarian clear cell carcinoma biology.

Authors:  Ken Yamaguchi; Zhiqing Huang; Noriomi Matsumura; Masaki Mandai; Takako Okamoto; Tsukasa Baba; Ikuo Konishi; Andrew Berchuck; Susan K Murphy
Journal:  Int J Cancer       Date:  2014-01-14       Impact factor: 7.396

3.  Error-promoting DNA synthesis in ovarian cancer cells.

Authors:  Heqiao Dai; Robert J Hickey; Jianying Liu; Robert M Bigsby; Carita Lanner; Linda H Malkas
Journal:  Gynecol Oncol       Date:  2013-07-12       Impact factor: 5.482

4.  Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model.

Authors:  Paul C Roberts; Emilio P Mottillo; Andrea C Baxa; Henry H Q Heng; Nicole Doyon-Reale; Lucie Gregoire; Wayne D Lancaster; Raja Rabah; Eva M Schmelz
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

5.  Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors.

Authors:  M Ehrlich; C B Woods; M C Yu; L Dubeau; F Yang; M Campan; D J Weisenberger; Ti Long; B Youn; E S Fiala; P W Laird
Journal:  Oncogene       Date:  2006-04-27       Impact factor: 9.867

6.  DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.

Authors:  Sahar Houshdaran; Sarah Hawley; Chana Palmer; Mihaela Campan; Mari N Olsen; Aviva P Ventura; Beatrice S Knudsen; Charles W Drescher; Nicole D Urban; Patrick O Brown; Peter W Laird
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

Review 7.  Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.

Authors:  Daniela E Matei; Kenneth P Nephew
Journal:  Gynecol Oncol       Date:  2009-10-24       Impact factor: 5.482

8.  A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

Authors:  Ya-Ting Yang; Curt Balch; Samuel K Kulp; Michael R Mand; Kenneth P Nephew; Ching-Shih Chen
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

9.  Fetal and neonatal exposure to the endocrine disruptor methoxychlor causes epigenetic alterations in adult ovarian genes.

Authors:  Aparna Mahakali Zama; Mehmet Uzumcu
Journal:  Endocrinology       Date:  2009-07-09       Impact factor: 4.736

10.  Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer.

Authors:  Michael Wy Chan; Yi-Wen Huang; Corinna Hartman-Frey; Chieh-Ti Kuo; Daniel Deatherage; Huaxia Qin; Alfred Sl Cheng; Pearlly S Yan; Ramana V Davuluri; Tim H-M Huang; Kenneth P Nephew; Huey-Jen L Lin
Journal:  Neoplasia       Date:  2008-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.